Keisuke Seike

Keisuke Seike

Auto-generated profile, based on publicly available information

Keisuke Seike

Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RKRoshan Kumar
Roshan Kumar
ALAaron P. Landry
Aaron P. Landry
AGArkajit Guha
Arkajit Guha
VVVictor Vitvitsky
Victor Vitvitsky
HLHo Joon Lee
Ho Joon Lee
RBRuma Banerjee
Ruma Banerjee
The dual roles of H2S as an endogenously synthesized respiratory substrate and as a toxin raise questions as to how it is cleared when the electron transport chain is inhibited. Sulfide quinone oxidoreductase (SQOR) catalyzes the first step in the mitochondrial H2S oxidation pathway, using CoQ as an electron acceptor, and connects to the electron transport chain at the level of complex III. We have discovered that at high H2S concentrations, which are known to inhibit complex IV, a new redox cycle is established between SQOR and complex II, operating in reverse. Under these conditions, the purine nucleotide cycle and the malate aspartate shuttle furnish fumarate, which supports complex II reversal and leads to succinate accumulation. Complex II knockdown in colonocytes decreases the efficiency of H2S clearance while targeted knockout of complex II in intestinal epithelial cells significantly decreases the levels of thiosulfate, a biomarker of H2S oxidation, to approximately one-third of the values seen in serum and urine samples from control mice. These data establish the physiological relevance of this newly discovered redox circuitry between SQOR and complex II for prioritizing H2S oxidation and reveal the quantitatively significant contribution of intestinal epithelial cells to systemic H2S metabolism.

2 February 2023 in Immunity
Verified
Journal Article
Closed access
KSKeisuke Seike
Keisuke Seike
AKAnders Kiledal
Anders Kiledal
HFHideaki Fujiwara
Hideaki Fujiwara
IHIsrael Henig
Israel Henig
MSMarina Burgos da Silva
Marina Burgos da Silva
PRPavan Reddy
Pavan Reddy

22 January 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
KSKeisuke Seike
Keisuke Seike
NFNobuharu Fujii
Nobuharu Fujii
NANaomi Asano
Naomi Asano
SOShigenori Ohkuma
Shigenori Ohkuma
YHYasushi Hirata
Yasushi Hirata
YMYoshinobu Maeda
Yoshinobu Maeda

1 July 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TTToshiki Terao
Toshiki Terao
WKWataru Kitamura
Wataru Kitamura
NFNobuharu Fujii
Nobuharu Fujii
NANoboru Asada
Noboru Asada
CKChihiro Kamoi
Chihiro Kamoi
YMYoshinobu Maeda
Yoshinobu Maeda
The prognostic impact of corticosteroid therapy for patients with tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) still remains unclear. This study aimed to evaluate the clinical impact and lymphocyte kinetics of corticosteroid administration for CRS in 45 patients with relapsed and/or refractory B-cell lymphoma treated with tisa-cel. This was a retrospective evaluation of all consecutive patients diagnosed with relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma with histologic transformation to large B-cell lymphoma, or follicular lymphoma who received commercial-based tisa-cel treatment. The best overall response rate, complete response rate, median progression-free survival (PFS), and median overall survival (OS) were 72.7%, 45.5%, 6.6 months, and 15.3 months, respectively. CRS (predominantly grade 1/2) occurred in 40 patients (88.9%), while ICANS (all grade) occurred in 3 patients (6.7%). No grade 3 or higher ICANS occurred. Patients with high-dose (≥ 524 mg, methylprednisolone equivalent, n = 12) or long-term (≥ 8 days, n = 9) corticosteroid use had inferior PFS and OS to patients with low or no corticosteroid use (both p < 0.05). The prognostic impact remained even in 23 patients with stable (SD) or progressive disease (PD) before tisa-cel infusion (p = 0.015) but not in patients with better disease status (p = 0.71). The timing of corticosteroid initiation did not have a prognostic impact. Multivariate analysis revealed that high-dose or long-term corticosteroid use were the independent prognostic factors of PFS and OS, respectively, after adjusting for elevated LDH before lymphodepletion chemotherapy and disease status (SD or PD). Lymphocyte kinetics analysis demonstrated that after methylprednisolone administration, the proportion of regulatory T-cells (Tregs), CD4+ central memory T (TCM) cells, and NK-cells were decreased, while that of CD4+ effector memory T (TEM) cells was increased. Patients with the higher proportion of Tregs at day 7 had a lower incidence of CRS, but this did not affect prognosis, indicating that early elevation of Tregs may serve as a biomarker for CRS development. Furthermore, patients with the higher number of CD4+ TCM cells and NK-cells at various time points had significantly better PFS and OS, whereas the number of CD4+ TEM cells did not impact prognostic outcomes. This study suggested that high-dose or long-term corticosteroid use attenuates the efficacy of tisa-cel, especially in patients with SD or PD. Additionally, patients with the high level of CD4+ TCM cells and NK-cells after tisa-cel infusion have longer PFS and OS.

20 December 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AYAkira Yamamoto
Akira Yamamoto
NFNobuharu Fujii
Nobuharu Fujii
KSKeisuke Seike
Keisuke Seike
SSSeiichiro Sugimoto
Seiichiro Sugimoto
YNYusuke Naoi
Yusuke Naoi
YMYoshinobu Maeda
Yoshinobu Maeda
Bronchiolitis obliterans (BO) is a severe, fibrotic manifestation of chronic graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Macrophage-derived TGF-β is linked to GVHD-related fibrosis; however, its role in BO remains unclear. Given emerging evidence of macrophage-to-myofibroblast transition (MMT) in fibrosis, this study aimed to investigate whether MMT contributes to BO development. We analyzed lung samples from three HSCT recipients with BO who underwent lung transplantation, with tissues from two patients with lung cancer as controls. Immunofluorescent staining for CD68, CD206, and α-SMA was used to identify cells undergoing MMT. Spatial transcriptomics was performed to profile gene expression in foamy macrophages across anatomical regions and histological stages, compared to control peribronchiolar regions. Immunostaining showed strong co-expression of CD68, CD206, and α-SMA in foamy macrophages within and surrounding bronchioles in BO samples, with minimal expression in controls, suggesting MMT involvement. In BO, spatial transcriptomics revealed upregulation of macrophage- and TGF-β signaling genes, with distinct stage- and region-specific gene expression patterns. Unsupervised clustering revealed a shift from inflammation to fibrosis. These findings indicate that MMT contributes to fibrosis in BO. Gene expression shifts from inflammation to fibrosis as the disease advances, underscoring the importance of early intervention.

17 June 2025 in International Journal of Hematology
Verified
Journal Article
Open access
PDF file
KHKenta Hayashino
Kenta Hayashino
KSKeisuke Seike
Keisuke Seike
TMTaro Masunari
Taro Masunari
RHRisa Hashida
Risa Hashida
SOSatoshi Oka
Satoshi Oka
YMYoshinobu Maeda
Yoshinobu Maeda
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes of relapsed and/or refractory large B-cell lymphoma (r/r LBCL). However, its off-tumor effects result in severe prolonged humoral immune deficiency. Cytomegalovirus (CMV) is a latent virus that can be life-threatening in immunosuppressed patients. In the setting of CAR T-cell therapy, Asian race is a risk factor for clinically significant CMV infection. However, the effect of CAR T-cell therapy on CMV reactivation in Japanese patients remains unclear. Previous reports used polymerase chain reaction (PCR), but we used the pp65 antigenemia assay to retrospectively investigate long-term effects in patients with r/r LBCL. The study included 46 patients. Nine (19.6%) developed CMV reactivation, with a median onset of 13 days. Six of these patients received preemptive therapy, and none developed CMV end-organ disease. Primary refractory disease, grade 2–4 cytokine release syndrome, and high-dose corticosteroids were risk factors for CMV reactivation. Long-term follow-up showed that CMV reactivation rarely occurred later than 28 days post-infusion. Our study using the pp65 antigenemia assay showed a similar incidence of CMV reactivation, onset, and risk factors to those in the previous reports using PCR.